Initial Technical and Clinical Validation of Mobile Pupillometry with Virtual Reality: A Digital Biomarker for Screening Cognitive Function and Impairment

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Cognitive impairment is a prevalent symptom extending from physiological ageing to disease. It commonly manifests itself in initial memory problems, progressing and co-occurring in more severe conditions such as Mild Cognitive Impairment, Alzheimer’s Disease and Major Depressive Disorder. However, current non-invasive screening assessments either lack biological information or are invasive and restricted to specialized centers with complex and cost-intensive set-ups. Here, we conducted an initial validation of mobile pupillometry with Virtual Reality (VR) under experimental conditions as a digital biomarker for cognitive impairment by testing required biomarker-specific properties. For this purpose, we first assessed its construct validity by testing healthy participants (n=43) on an n-back task in VR while pupil size was measured. Mixed effects models revealed that similar to lab-based eye-tracking systems, pupil size increased in a sensible and distinguishable fashion as a function of working memory load. Second, to test the signal’s reliability, the same participants were tested on the identical set-up two to three months after their first visit. We observed that the pupil response profile was highly stable over this period. Third, for its clinical validity, we examined patients (n=89) from three different cohorts with varying degrees of cognitive impairment and compared them to healthy control participants (n=81). Mixed-effects models indicated that pupil size was reduced as a function of cognitive impairment levels at higher cognitive load and that this effect was stronger pronounced with increasing age. In conclusion, we provide initial evidence for mobile pupillometry being a sensitive, reliable and clinically valid digital biomarker for cognitive functioning and impairment, which offers desirable properties due to its quick, automatized and location-independent set-up.

Article activity feed